Innate Pharma SA (IPHA) Earnings Date & Reports

Key Takeaways

• Revenue for the first nine months of 2026 reached €3.4 million, up from €2.3 million in the same period of 2025, driven by collaboration and licensing agreements with AstraZeneca and Sanofi.
• Cash, cash equivalents, and financial assets stood at €96.8 million as of September 30, 2026, boosted by the $75 million upfront payment from the Sobi partnership and a €30 million private placement.
• Management extended its projected cash runway through the end of the first quarter of 2028, giving the company flexibility to advance its clinical pipeline.
• Initial Phase 1 dose-escalation data for IPH4502, a Nectin-4 antibody-drug conjugate (ADC), is scheduled for presentation at ENA 2026 on November 18.
• The lacutamab program, partnered with Sobi, is progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027.
• The PACIFIC-9 Phase 3 readout, run by AstraZeneca for monalizumab, has been updated to the first half of 2027.
• For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Interested in automated market ideas? Discover Trending AI Robots.

Earnings Context and Why It Matters

Innate Pharma, a clinical-stage biotechnology company headquartered in Marseille, France, develops immunotherapies for cancer. Its proprietary pipeline is anchored by IPH4502, a differentiated Nectin-4 ADC, alongside partnered late-stage assets lacutamab (with Sobi) and monalizumab (with AstraZeneca). Because the company generates revenue primarily from collaborations rather than marketed products, its quarterly updates matter less for top-line sales and more for cash position, clinical catalysts, and partnership milestones. The third-quarter 2026 update arrives at a pivotal moment, with the Sobi transaction closing and multiple data readouts approaching. Investors are watching whether the strengthened balance sheet and upcoming catalysts can support the company's valuation after a period of heavy cash burn and share-price pressure.

Reported Results

Innate Pharma reported revenue of €3.4 million for the nine months ended September 30, 2026, compared with €2.3 million in the prior-year period. The increase was driven mainly by the recognition of collaboration and licensing revenue tied to agreements with AstraZeneca and Sanofi.

The company's cash, cash equivalents, and financial assets totaled €96.8 million at the end of the quarter. This balance includes the $75 million upfront payment received from closing the Sobi partnership and gross proceeds from a €30 million private placement completed in August 2026. Financial liabilities stood at €16.2 million as of September 30, 2026. The company reiterated that its cash runway is now expected to extend through the end of the first quarter of 2028.

On the clinical front, enrollment in the Phase 1 study of IPH4502 was completed in July 2026, with preliminary antitumor activity observed in heavily pretreated patients. Management also confirmed that the PACIFIC-9 Phase 3 trial readout timeline has shifted to the first half of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Innate Pharma, the AI Screener offers a structured way to surface opportunities across the biotechnology sector and beyond.

Market Reaction and Investor Sentiment

Innate Pharma shares have traded well below their 52-week high, reflecting caution around a clinical-stage company that remains loss-making with limited near-term product revenue. The stock's elevated price-to-sales ratio signals that investors are pricing in future pipeline value rather than current fundamentals. Heading into this update, sentiment was focused on the company's ability to preserve its balance sheet and deliver on near-term catalysts. The extended cash runway through early 2028 reduces immediate financing risk, but the market remains attentive to whether upcoming clinical readouts, particularly for IPH4502 and the PACIFIC-9 program, can validate the company's development strategy.

Forward Outlook and Key Factors to Monitor

The most immediate catalyst is the presentation of initial Phase 1 dose-escalation data for IPH4502 at ENA 2026 on November 18. Because this ADC targets Nectin-4 and has shown preliminary responses in heavily pretreated patients, the data will be closely scrutinized for durability of response and safety signals.

Looking further ahead, the lacutamab program carries significant weight. Innate and partner Sobi expect first patient dosing in the Phase 3 TELLOMAK-3 trial in the first quarter of 2027, with a planned filing for accelerated approval in Sézary syndrome during the second half of 2027.

Investors should also monitor the PACIFIC-9 Phase 3 readout, which AstraZeneca now expects in the first half of 2027. Given that monalizumab revenue recognition has already been completed, this readout is primarily a scientific and strategic catalyst.

Finally, cash discipline remains central. While the runway extends to early 2028, advancing the pipeline further or broadening clinical programs could require additional funding. Key factors to watch include operating expense trends, any changes to partnership economics, and the company's ability to convert clinical momentum into long-term value.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations